Immunogenicity in stem cell therapy for cardiac regeneration

Yi Hsien Fang, Saprina P.H. Wang, Hsien Yuan Chang, Pei Jung Yang, Ping Yen Liu, Yen Wen Liu

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Despite enormous advances in the treatment of cardiovascular disease (CVD), heart disease remains the leading cause of mortality and morbidity worldwide. Thus, there is a need for novel CVD therapeutics. CVD appears to be a custom-made scenario for applying stem cell therapy. Although human pluripotent stem cells can differentiate into cardiomyocytes to regenerate injured heart tissue and restore post-myocardial infarction cardiac function, several obstacles need to be overcome before cell therapy can be applied in CVD patients.One of these major hurdlesis the immunological barrier. Currently, long-term immunosuppressant treatment is necessary for allogenic stem cell or organ transplantation to prevent rejection. However, the long-term use of immune suppressants may cause serious adverse events such as nephrotoxicity, severe infections and malignancy. Thus, overcoming this immunological hurdle is crucial for the clinical application of stem cell therapy in cardiac regeneration. This review summarizes the recent advances and challenges of immunogenicity in relation to stem cell therapy.

Original languageEnglish
Pages (from-to)588-594
Number of pages7
JournalActa Cardiologica Sinica
Issue number6
Publication statusPublished - 2020 Nov

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Immunogenicity in stem cell therapy for cardiac regeneration'. Together they form a unique fingerprint.

Cite this